Table 5.

Model 2: Relative incidence of adverse events of interest and interaction term for vaccine type.

	RI	95% CI	p
Exposure risk period (with date of vaccination as day 0)
Days 0 to 6	2.42	2.30–2.55	<0.001
Time from start of influenza season (reference: Days 0 to 29)
Days 30 to 59	1.00	0.99–1.02	0.557
Days 60 to 89	1.05	1.04–1.07	<0.001
Days 90 to 119	0.91	0.90–0.92	<0.001
Days 120 to 149	1.12	1.11–1.14	<0.001
Days 150 to 179	1.11	1.09–1.12	<0.001
Days 180 to 209	0.88	0.86–0.89	<0.001
Days 210 to 241	0.57	0.56–0.58	<0.001
Vaccination type (reference: QIVc)
QIVe	0.96	0.90–1.02	0.148
LAIV	0.57	0.53–0.61	<0.001
aTIV	0.74	0.70–0.78	<0.001

Note. QIVc: cell culture-based quadrivalent influenza vaccine; egg-based quadrivalent influenza vaccine; LAIV: live attenuated influenza vaccine; aTIV: adjuvanted trivalent influenza vaccine.